Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: Safety and efficacy in patients with and without cardiac resynchronization therapy

European Journal of Heart Failure

Volumn 17, Issue 10, 2015, Pages 1066-1074

  Zile, Michael R ^a,o   Abraham, William T ^b   Weaver, Fred A ^c   Butter, Christian ^d   Ducharme, Anique ^e   Halbach, Marcel ^f   Klug, Didier ^g   Lovett, Eric G ^h   Müller Ehmsen, Jochen ⁱ   Schafer, Jill E ^j   Senni, Michele ^k   Swarup, Vijay ^l   Wachter, Rolf ^m   Little, William C ⁿ  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d BRANDENBURG MEDICAL SCHOOL THEODOR FONTANE   (Germany)

^e MONTREAL HEART INSTITUTE   (Canada)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CVRX INC   (United States)

ⁱ ASKLEPIOS KLINIK ALTONA   (Germany)

^j NAMSA Inc   (United States)

^k PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^l Arizona Heart Hospital   (United States)

^m UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁿ UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^o RALPH H JOHNSON VA MEDICAL CENTER   (United States)

more..

Author keywords

Autonomic nervous system; Baroreflex; Heart failure; Randomized controlled trial; Resynchronization

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; MINERALOCORTICOID ANTAGONIST;

6-MIN HALL WALK DISTANCE; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BAROREFLEX ACTIVATION THERAPY; BAROREFLEX ACTIVATION THERAPY DEVICE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EQUIPMENT; CARDIOVASCULAR PROCEDURE; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE THERAPY; EXERCISE TEST; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MINNESOTA LIVING WITH HEART FAILURE QUALITY OF LIFE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARASYMPATHETIC TONE; PATIENT CODING; PATIENT SAFETY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPATHETIC TONE; TREATMENT RESPONSE; ELECTROTHERAPY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; IMPLANTABLE NEUROSTIMULATOR; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; BAROREFLEX; CARDIAC RESYNCHRONIZATION THERAPY; ELECTRIC STIMULATION THERAPY; FEMALE; HEART FAILURE; HUMANS; IMPLANTABLE NEUROSTIMULATORS; MALE; MIDDLE AGED; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84946483529     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.299     Document Type: Article

References (26)

1. Floras JS,. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009; 54; 375-385.
2. Ponikowski P, Anker SD, Chua TP, Szelemej R, Piepoli M, Adamopoulos S, Webb-Peploe K, Harrington D, Banasiak W, Wrabec K, Coats AJ,. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79: 1645-1650.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
4. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N,. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2817-2825.
5. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ,; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-667.
6. Georgakopoulos D, Little WC, Abraham WT, Weaver FA, Zile MR,. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail 2011; 17: 167-178.
7. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H,. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6: 270-276.
8. Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G,. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014; 16: 977-983.
9. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC,. Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction. JACC-HF 2015; DOI: 10.1016/j.jchf.2015.02.006
10. DeMazumder D, Kass DA, O'Rourke B, Tomaselli GF,. Cardiac resynchronization therapy restores sympathovagal balance in the failing heart by differential remodeling of cholinergic signaling. Circ Res 2015; 116: 1691-1699.
11. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edn. Boston: Little, Brown, 1994.
12. Rector RS, Kubo SH, Cohn JN,. Patients' self-assessment of their congestive heart failure. II. Content, reliability, and validity of a new measure-the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987; 3: 198-209.
13. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB,. The 6 minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-923.
14. Madershahian N, Scherner M, Müller-Ehmsen J, Halbach M, Hickethier T, Velden R, Choi YH, Wippermann J, Wahlers T,. Baroreflex activation therapy in patients with pre-existing implantable cardioverterdefibrillator: compatible, complementary therapies. Europace 2014; 16: 861-865.
15. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J,; MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
16. Fowler MB,. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Eur Heart J 1998; 19 (Suppl. P): P17-P25.
17. Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hellmich M, Erdmann E, Schneider CA,. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 2008; 10: 315-320.
18. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC,. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662-673.
19. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation 2013; 128: e240-e327.
21. Premchand RK, Sharma K, Mittal S, Monteiro R, Dixit S, Libbus I, DiCarlo LA, Ardell JL, Rector TS, Amurthur B, KenKnight BH, Anand IS,. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail 2014; 20: 808-816.
22. Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D'Onofrio A, Solomon SD, Wold N, Ruble SB,. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015; 36: 425-433.
23. Mortara AL, La Rovere MT, Pinna GD, Prpa A, Maestri R, Febo O, Pozzoli M, Opasich C, Tavazzi L,. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997; 96 3450-3458.
24. La Rovere MT, Pinna GD, Maestri R, Barlera S, Bernardinangeli M, Veniani M, Nicolosi GL, Marchioli R, Tavazzi L,; GISSI-HF Investigators. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. Eur J Heart Fail 2012; 14: 1410-1419.
25. La Rovere MT1, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, Sleight P, Febo O,. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol 2009; 53: 193-199
26. Gademan MGL, van Bommel RJ, Ypenburg C, Haest JC, Schalij MJ, van der Wall EE, Bax JJ, Swenne CA,. Biventricular pacing in chronic heart failure acutely facilitates the arterial baroreflex. Am J Physiol Heart Circ Physiol 2008; 295: H755-H760.